PR Newswire/Les Echos/

STALLERGENES

PRESS RELEASE

                        STRONG SALES GROWTH IN Q4: UP 15%
               2009 SALES GUIDANCE EXCEEDED: 193 MILLION, UP 13%

Antony, France; 14 January 2010 - 6 pm.

(EUR millions)             2008         08/07              2009         09/08
               EUR millions    %sales  %change  EUR millions  %sales   %change
Southern Europe(1)   36.4      73       14         42.4         74        16
Other EU (2)         11.3      23       17         13.1         23        16
Other markets         2.0       4       45          1.5          3       (25)
SLIT                 40.4      81       17         48.5         85        20
SCIT                  7.5      15        6          6.8         12       (10)
Other products        1.8       4       32          1.7          3        (5)
Total Q4 sales       49.7     100       15         57.0        100        15

(EUR millions)             2008         08/07           2009           09/08
               EUR millions    %sales  %change EUR millions  %sales   %change
Southern Europe (1) 124.9      73       14        138.6        72        11
Other EU (2)         38.5      23       18         47.6        25        24
Other markets         7.5       4       38          6.7         3       (11)
SLIT                137.9      81       18        160.0        83        16
SCIT                 26.3      15        6         25.9        13        (2)
Other products        6.7       4       16          6.9         4         4
Cumulative 12
month sales         170.9     100       16        192.8       100        13

(1) Portugal, Spain, France, Italy, Greece; (2) Switzerland included

Sales growth and financial position

Sales growth sped up over the fourth quarter to 15%, 3 percentage points higher
than that of third quarter 2009. The markets of Northern Europe ("Other EU") and
the sublingual route drove this progression but the markets of Southern Europe
had an encouraging recovery in growth over the last quarter. Other markets were
affected by a negative basis effect due to the strong growth achieved in 2008.
Organic growth, after restatement for foreign exchange effects stood at 13% over
the quarter and 12% over the full year.

As a consequence, results for the year will markedly improve: operating profit
and net profit as a percentage of sales should remain close to the levels
achieved in 2008 (16% and 11%, respectively). The Company had a positive net
cash position at the end of the financial year.
The comprehensive 2009 results will be published on 16 March 2010 after close of
trading.
As for 2010, the Group is currently expecting significant growth and a further
improvement in its results due to the limitation put on R&D expenses.

Significant 4th quarter transactions and events

Following the mutual recognition procedure, Oralair(r) (immunotherapy tablet for
grass pollen) was granted a marketing authorisation in 22 European countries in
its adult and paediatric indications on 27 November 2009.

The outstanding results of the study devoted to showing the long-term sustained
effect of Oralair(r) were announced on 7 December 2009. They significantly
confirmed the clinical relevance of Oralair(r). This study is being continued
with a view to demonstrating the persistence of the effect after completion of
the treatment (carry-over effect), which should be the subject of an
announcement at the end of 2010.

The Oralair(r) phase III clinical study in the US was completed in good
conditions. Talks are ongoing with the FDA on statistical analysis matters.
These exchanges have no impact on the results of the study but must be concluded
before the database is opened for analysis. Consequently, the delivery of the
preliminary results will take place in a few weeks.
The authorisation to carry out a Phase III clinical study on children for
Actair(r) (immunotherapy tablet for dust mites) on 450 patients has been granted
in Europe and patients are being recruited. The preliminary results should be
published in mid-201 1.

The presentation of the clinical results obtained in 2009 and at the start of
2010 will be the subject of a specific meeting, to be organised shortly.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical laboratory specialising in
treatments by immunotherapy for the prevention and treatment of allergy-related
respiratory conditions, such as rhino conjunctivitis, rhinitis and allergic
asthma. Stallergenes is ranked seventh among French pharmaceutical laboratories.
A pioneer and a leader in immunotherapy treatments by sublingual administration,
Stallergenes dedicates 21% (gross) of its sales to its Research and Development
activities, which are primarily directed at developing a new therapeutic range
enabling the provision of immunotherapy treatments by sublingual tablets.

Stallergenes realised 2009 sales of EUR193 million, with over 500,000 patients
treated with Stallergenes desensitisation products.

Euronext Paris (Compartment B).
SBF 120 index.
ISIN code: FR0000065674
Reuters code: GEN.PA
Bloomberg code: GEN.FP

For further financial information, please visit our website:
http://www.stallergenes.com 

Contacts
Albert Saporta, Chairman and CEO
Tel. +33 1 55 59 20 04
Christian Thiry, Chief Financial Officer
Tel. +33 1 55 59 20 95
e-mail: investorrelations@stallergenes.fr

Investor and Analyst Relations
Lucile de Fraguier, Pavie Finance
Tel. +33 1 42 15 04 39
e-mail: contact@pavie-finance.com 

Stallergenes Press Relations
Lise Lemonnier, Communication Officer
Tel. + 33 1 55 59 20 96
e-mail: llemonnier@stallergenes.fr
                      
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication.